Literature DB >> 24975321

The molecular arms race between African trypanosomes and humans.

Etienne Pays1, Benoit Vanhollebeke1, Pierrick Uzureau2, Laurence Lecordier1, David Pérez-Morga1.   

Abstract

Humans can survive bloodstream infection by African trypanosomes, owing to the activity of serum complexes that have efficient trypanosome-killing ability. The two trypanosome subspecies that are responsible for human sleeping sickness--Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense--can evade this defence mechanism by expressing distinct resistance proteins. In turn, sequence variation in the gene that encodes the trypanosome-killing component in human serum has enabled populations in western Africa to restore resistance to T. b. rhodesiense, at the expense of the high probability of developing kidney sclerosis. These findings highlight the importance of resistance to trypanosomes in human evolution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24975321     DOI: 10.1038/nrmicro3298

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  90 in total

1.  Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes.

Authors:  J Drain; J R Bishop; S L Hajduk
Journal:  J Biol Chem       Date:  2001-05-14       Impact factor: 5.157

2.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

Review 3.  Lysosomal membrane permeabilization in cell death.

Authors:  P Boya; G Kroemer
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

4.  The innate immune factor apolipoprotein L1 restricts HIV-1 infection.

Authors:  Harry E Taylor; Atanu K Khatua; Waldemar Popik
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

5.  Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes.

Authors:  Maria del Pilar Molina-Portela; Elena B Lugli; Esperanza Recio-Pinto; Jayne Raper
Journal:  Mol Biochem Parasitol       Date:  2005-09-19       Impact factor: 1.759

6.  Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L.

Authors:  P N Duchateau; C R Pullinger; R E Orellana; S T Kunitake; J Naya-Vigne; P M O'Connor; M J Malloy; J P Kane
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

Review 7.  The function of apolipoproteins L.

Authors:  B Vanhollebeke; E Pays
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

8.  C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense.

Authors:  Laurence Lecordier; Benoit Vanhollebeke; Philippe Poelvoorde; Patricia Tebabi; Françoise Paturiaux-Hanocq; Fabienne Andris; Laurence Lins; Etienne Pays
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

9.  Killing of trypanosomes by the human haptoglobin-related protein.

Authors:  A B Smith; J D Esko; S L Hajduk
Journal:  Science       Date:  1995-04-14       Impact factor: 47.728

10.  Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum.

Authors:  Benoit Vanhollebeke; Marianne J Nielsen; Yoshihisa Watanabe; Philippe Truc; Luc Vanhamme; Kazunori Nakajima; Soren K Moestrup; Etienne Pays
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

View more
  47 in total

Review 1.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

2.  Identifying the Intracellular Function of APOL1.

Authors:  Leslie A Bruggeman; John F O'Toole; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-02-14       Impact factor: 10.121

3.  Apolipoprotein L1 confers pH-switchable ion permeability to phospholipid vesicles.

Authors:  Jonathan Bruno; Nicola Pozzi; Jonathan Oliva; John C Edwards
Journal:  J Biol Chem       Date:  2017-09-15       Impact factor: 5.157

Review 4.  Severe infectious diseases of childhood as monogenic inborn errors of immunity.

Authors:  Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

Review 5.  Human genetic basis of interindividual variability in the course of infection.

Authors:  Jean-Laurent Casanova
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

6.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20

Review 7.  The Cell Biology of APOL1.

Authors:  John F O'Toole; Leslie A Bruggeman; Sethu Madhavan; John R Sedor
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

Review 8.  APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?

Authors:  Opeyemi A Olabisi; John F Heneghan
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

Review 9.  APOL1 Kidney Disease Risk Variants: An Evolving Landscape.

Authors:  Patrick D Dummer; Sophie Limou; Avi Z Rosenberg; Jurgen Heymann; George Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Semin Nephrol       Date:  2015-05       Impact factor: 5.299

10.  Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.

Authors:  Alok K Sharma; David J Friedman; Martin R Pollak; Seth L Alper
Journal:  FEBS J       Date:  2016-04-01       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.